Journal Article

Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost

Joachim, Agricola, Lyamuya, Eligius F., Wahren, Britta, Bakari, Muhammad, Aboud, Said, Hoffmann, Verena S., Robb, Merlin L., Nilsson, Charlotta, Rogers, Lisa, Biberfeld, Gunnel, Ahmed, Mohamed I. M., Munseri, Patricia, Geldmacher, Christof, Held, Kathrin, Sandstrom, Eric, Pollakis, Georgios

2020

Overview

In the RV144 trial, to date the only HIV-1 vaccine efficacy trial demonstrating a modestly reduced risk of HIV-1 acquisition, antibody responses toward the HIV Envelope protein (Env) variable (V) 2 and V3 regions were shown to be correlated with a reduced risk of infection. These potentially protective antibody responses, in parallel with the vaccine efficacy, however, waned quickly. Dissecting vaccine-induced IgG recognition of antigenic regions and their variants within the HIV-1 Env from different vaccine trials will aid in designing future HIV-1 immunogens and vaccination schedules. We, therefore, analyzed the IgG response toward linear HIV-1 Env epitopes elicited by a multi-clade, multigene HIVIS-DNA priming, and heterologous recombinant modified vaccinia virus Ankara (MVA-CMDR) boosting regimen (HIVIS03) and assessed whether a late MVA-CMDR boost 3 years after completion of the initial vaccination schedule (HIVIS06) restored antibody responses toward these epitopes. Here we report that vaccination schedule in the HIVIS03 trial elicited IgG responses against linear epitopes within the V2 and V3 tip as well as against the gp41 immunodominant region in a high proportion of vaccinees. Antibodies against the V2 and gp41 Env regions were restricted to variants with close homology to the MVA-CMDR immunogen sequence, while V3 responses were more cross-reactive. Boosting with a late third MVA-CMDR after 3 years effectively restored waned IgG responses to linear Env epitopes and induced targeting of identical antigenic regions and variants comparable to the previous combined HIVIS-DNA/MVA-CMDR regimen. Our findings support the notion that anti-HIV-1 Env responses, associated with a reduced risk of infection in RV144, could be maintained by regular boosting with a single dose of MVA-CMDR.

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: AIDS Vaccines - immunology / AIDS Vaccines - therapeutic use / Antibodies / Antibodies, Neutralizing - immunology / Antiviral agents / Cross Reactions / Deoxyribonucleic acid / DNA / envelope (Env) / envelope-specific antibody response / epitope variants / Epitopes / Epitopes - immunology / Ethics / Glycoprotein gp41 / Healthy Volunteers / HIV / HIV Antibodies - immunology / HIV Envelope Protein gp120 - genetics / HIV Envelope Protein gp120 - immunology / HIV Envelope Protein gp41 - immunology / HIV Infections - prevention & control / HIV Infections - virology / HIV-1 - immunology / Homology / Human immunodeficiency virus / human immunodeficiency virus 1 (HIV-1) / Humans / Immunization Schedule / Immunization, Secondary - methods / immunogen structure / Immunoglobulin G / Immunoglobulin G - immunology / Immunology / Infections / Peptide Fragments - genetics / Peptide Fragments - immunology / Peptides / Phylogeny / Plasma / Plasmids / vaccine / Vaccine efficacy / Vaccines / Vaccines, DNA - immunology / Viral envelope proteins / Viral Vaccines - immunology / Viruses